Patent · US Active

Nucleoside-modified mRNA-lipid nanoparticle lineage vaccine for hepatitis C virus

US11660332B2 · kind B2 · utility

0Cited by

1References

8Claims

0Family size

Assignees

The Trustees of the University of Pennsylvania · US
THE JOHNS HOPKINS UNIVERSITY · US
VANDERBILT UNIVERSITY · US

Inventors

Drew Weissman · Wynnebrook Manor, US
George M. Shaw · Birmingham, US
Justin R. Bailey · Timonium, US
Stuart C. Ray · Timonium, US
James E. Crowe, Jr. · Nashville, US
Andrew Flyak · Nashville, US

Key dates

Filing date	Apr 27, 2018
Grant date	May 30, 2023
Priority date	—
Expiry date	Apr 27, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2770/24234
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to compositions and methods for inducing an adaptive immune response against Hepatitis C virus (HCV) in a subject. In some embodiments, the present invention provides a composition comprising a nucleoside-modified nucleic acid molecule encoding a HCV antigen, adjuvant, or a combination thereof. For example, in some embodiments, the composition comprises a vaccine comprising a nucleoside-modified nucleic acid molecule encoding a HCV antigen, adjuvant, or a combination thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.